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Abstract: Recently, a range of prescription and over-the-counter drugs have been reportedly used
as Novel Psychoactive Substances (NPS), due to their potential for abuse resulting from their high
dosage/idiosyncratic methods of self-administration. This paper provides a systematic review of the
topic, focusing on a range of medications which have emerged as being used recreationally, either on
their own or in combination with NPS. Among gabapentinoids, pregabalin may present with higher
addictive liability levels than gabapentin, with pregabalin being mostly identified in the context
of opioid, polydrug intake. For antidepressants, their dopaminergic, stimulant-like, bupropion
activities may explain their recreational value and diversion from the therapeutic intended use.
In some vulnerable clients, a high dosage of venlafaxine (‘baby ecstasy’) is ingested for recreational
purposes, whilst the occurrence of a clinically-relevant withdrawal syndrome may be a significant
issue for all venlafaxine-treated patients. Considering second generation antipsychotics, olanzapine
appears to be ingested at very large dosages as an ‘ideal trip terminator’, whilst the immediate-release
quetiapine formulation may possess proper abuse liability levels. Within the image- and performance-
enhancing drugs (IPEDs) group, the beta-2 agonist clenbuterol (‘size zero pill’) is reported to be
self-administered for aggressive slimming purposes. Finally, high/very high dosage ingestion of
the antidiarrhoeal loperamide has shown recent increasing levels of popularity due to its central
recreational, anti-withdrawal, opiatergic effects. The emerging abuse of prescription drugs within the
context of a rapidly modifying drug scenario represents a challenge for psychiatry, public health and
drug-control policies.
Keywords: drug abuse; novel psychoactive substances; NPS; pharmacovigilance; prescribing
drugs’ abuse
1. Introduction
Novel Psychoactive Substances (NPS; ‘legal highs’ or ‘research chemicals’) are molecules designed
to mimic the effects of legal traditional recreational drugs with intense psychoactive effects and
virtual non-detectability in routine drug screenings. NPS include synthetic cannabinoids, cathinone
derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives,
phencyclidine-like dissociatives, piperazines, psychoactive plants/herbs and a range of prescribed
medications [1]. The term NPS was first used by United Nations Office on Drugs and Crime
(UNODC) to refer to “substances of abuse, either in a pure form or a preparation, that are not
controlled by the 1961 Single Convention on Narcotic Drugs or the 1961 Convention on Psychotropic
Substances, but which may pose a public health threat” [2]. At present, the emergence of NPS,
typically from outside Western countries [3], represents a considerable public health challenge.
Moreover, in order to circumvent the present controls and regulations, NPS are constantly diversifying
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and being replaced [4]. This is being facilitated by the growing number of anonymous online
marketplaces, called ‘cryptomarkets’, which host many anonymous sellers whilst using untraceable
cryptocurrencies [5]. NPS users report a range of reasons behind their preference for NPS as opposed
to traditional drugs such as cannabis, cocaine and heroin, including typical lack of detectability,
greater affordability, lack of stigma, and relative ease of online acquisition [6]. Recently, however,
the phenomenon of using prescription drugs in an idiosyncratic way to resemble, or counteract,
the effects of NPS, has increasingly been described. This phenomenon refers not only to high
potency opioids (e.g., fentanyl) and ‘exotic’/designer benzodiazepines—molecules already having been
reported to be addictive [1]—but also: gabapentinoids [7], a range of stimulants [1], antipsychotics [8],
antidepressants [9] and image- and performance-enhancing drugs (IPEDS, e.g., anabolic steroids,
vitamins, clenbuterol and salbutamol) [10]. Among over-the-counter drugs, the two most common
agents reportedly ingested in intentional abuse cases are the antitussive, dextromethorphan [11], and
loperamide, a common antidiarrhoeal drug [12].
Any pharmacovigilance approach aims to detect, assess, understand and hopefully prevent
adverse effects or any other medicine-related problems. From this point of view, there is a growing
attention on prescription drugs and their addictive liability levels/diversion potential [7,8,10,12].
As the intended and the actual use of medicines differ between clinical trials and real-world use,
pharmacovigilance activities are well placed to focus on the post-marketing phase. In Europe, those
activities are coordinated by the European Medicines Agency (EMA) [13] through EudraVigilance
(EV), which is the system for collecting, managing and analyzing information on suspected adverse
reactions to medicines which have been authorized in the European Economic Area (EEA) [14].
This paper aims to provide a systematic review of the available literature relating to a preselected
range of prescription medicines (pregabalin, gabapentin, quetiapine, olanzapine, venlafaxine,
bupropion, loperamide, clenbuterol and salbutamol) previously reported as possibly being misused as
NPS. For each molecule, a range of preclinical, epidemiological, and clinical pharmacological data will
be provided.
2. Materials and Methods
A systematic review was carried out, consistent with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines [15]. A literature search was performed on PubMed,
Medline/OvidSP (includes Embase), and Web-of-Science; the current search was completed in February
2018 and was not associated with any time restrictions. We focused on pregabalin, gabapentin, quetiapine,
olanzapine, venlafaxine, bupropion, clenbuterol, salbutamol and loperamide [Title/Abstract]. For each
molecule, a number of search terms [Title/Abstract] were considered as follows: ‘misuse’, ‘abuse’,
‘dependence’, ‘withdrawal’, ‘off-label use’ and ‘non-medical use’. In addition, the authors performed
further secondary searches by using the reference listing of all eligible papers. All titles/abstracts were
examined, and full texts of potentially relevant papers obtained. Relevant works were selected in order
to obtain a full representation of the available literature data on the selected topic. Eligible studies
were identified if they possessed a range of characteristics, including (1) peer-reviewed clinical/human
studies; (2) at least an abstract with estimates and/or full availability of results; and (3) focusing on the
misuse/abuse/dependence/withdrawal of pregabalin; gabapentin; quetiapine; olanzapine, venlafaxine,
bupropion, loperamide, clenbuterol and salbutamol. The entire range of literature papers were included,
e.g., experimental and observational studies; case reports; case series; and fatalities’ reports. Although
letters to the editor, conference proceedings, and book chapters were excluded from the systematic
review, they were still considered in the retrieval of further secondary searches. SC independently
extracted and collected relevant data; FS contributed to the analysis of the results and discussed possible
issues and disagreements during the revision of the paper with SC.
From an initial list of 171 studies, 151 were identified as relevant and appropriate in terms of
quality according to PRISMA checklists. Following this, duplicates, papers lacking an English abstract,
letters to the editor, animal studies and papers unrelated to the topic were excluded, and 128 papers
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were finally considered for the current study. A flow diagram (Figure 1) describes the reasons for study
inclusion/exclusion at each stage, is here provided.
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and Schifano [7] recently assessed the EMA EV database of pregabalin and gabapentin misuse-related
Adverse Drug Reactions (ADRs) over the last decade. According to the Proportional Reporting Ratio
(PRR) computation, abuse/dependence issues were more frequently reported for pregabalin compared
with gabapentin, hence confirming its higher addictive liability levels [7,22]. Furthermore, Emergency
Department presentations involving intentional drug overdoses recorded by the National Self-Harm
Registry (Ireland; 2007–2015), showed that gabapentinoids have been increasingly identified over
time, with high dosages and polydrug abuse being reported [23]. Indeed, gabapentinoid fatalities
are typically observed when these molecules are associated with other psychoactive drugs, especially
opioids and other sedatives whose effects are potentiated by gabapentinoids [24,25].
3.2. Antidepressants
Consistent with a worldwide rise in antidepressant consumption [26,27], bupropion and
venlafaxine have anecdotally emerged as increasingly being abused [1,28,29]. In examining a range
of online communities and specialized web services, several antidepressant misusers’ experiences
may be identified [20]. These reports emphasise both bupropion’s stimulant effects and venlafaxine’s
dissociative properties. Indeed, bupropion described as being ingested in very large quantities
(up to 4050 mg/day, roughly 14 times higher than the maximal therapeutic dosage) in order to
achieve an ‘amphetamine-like high’ [30]. In most abuse cases, its recreational use is associated with
oral or nasal administration, but intravenous use has also been reported [28,30–34]. Bupropion
pharmacology relies on its action both as a selective inhibitor of catecholamines (noradrenaline and
DA) reuptake [35,36], and as a non-competitive antagonist of nicotinic acetylcholine receptors, hence
being prescribed as well as an aid in smoking cessation [36]. Bupropion is known to be a cathinone
derivative, that is, a beta-ketone amphetamine analogue with dopaminergic and noradrenergic effects,
which may explain its misuse potential [37,38]. This is a reason for concern since bupropion is also
used ‘off-label’ in a range of conditions, including attention-deficit/hyperactivity disorder, chronic
fatigue, sexual dysfunction, and obesity. The adverse effects of bupropion misuse range from nasal
pain to irritability, agitation, cardiac toxicity, hallucinations and seizures [39,40]. A retrospective
review [41] on bupropion cases of intentional abuse reported to the US National Poison Data System
highlighted an increase of 75% from 2000 to 2012, with the typical effects reported including tachycardia,
seizures, agitation/irritability, hallucinations/delusions, and tremor; similar data were identified
by the Toxicology Data Network of the US National Institute of Health (Toxnet) [42]. Typical
bupropion abusers may present with a history of drug addiction [38,43,44] and/or are inmates, with
bupropion having been removed from some US prison formularies [45–47]. Conversely, venlafaxine
is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant, indicated [48] for
the treatment of major depressive episodes, generalised anxiety disorder and social phobia, with
off-label use including obsessive-compulsive disorder and chronic pain syndromes. Its reuptake
effects are dose-dependent, with action progressively including serotonin (5-HT), norepinefrine (NE)
and dopamine (DA). Venlafaxine’s main active metabolite, desvenlafaxine, is highly inhibitive of NE
transporter activities, further increasing the rate of DA turnover in the prefrontal cortex [49]. Both
venlafaxine and its metabolite are not associated with monoamine oxidase inhibitory activity, which is
responsible for the degradation of DA. Hence, venlafaxine abuse may be associated with DA increase
in the prefrontal cortex [50], high affinity for D2 receptors adaptive changes in D3 receptors following
its chronic administration and, finally, with the desensitisation of both 5-HT1A and beta-adrenergic
receptors [51]. Dependence and withdrawal symptoms associated with both SSRIs and SNRIs have
already been described, specifically with abrupt discontinuation of venlafaxine (including Extended
Release (XR) formulation) after long-term use [9,52–54]. Symptoms range from mild to severe and
include nausea, depression, suicidal thoughts, disorientation, stomach cramps, panic attacks, sexual
dysfunction, headaches and occasional psychotic symptoms [55–59]; a newborn discontinuation
syndrome has been described as well, at times associated with encephalopathy or paroxysmal
episodes [60]. The management of venlafaxine withdrawal includes the use of other antidepressants
Brain Sci. 2018, 8, 73 5 of 17
(Ads) or venlafaxine tapering doses [61,62]. Furthermore, venlafaxine/‘baby ecstasy’ abuse has been
reported, typically being the result of the intake of very large doses [63–65]. Consistent with this, studies
have assessed drug and pharmaceutical consumption in England through wastewater analysis and
comparing it to NHS prescription statistics. Discrepancies have been observed in the case of venlafaxine,
suggesting sales of non-prescribed venlafaxine, which are, therefore, not included within NHS data [66].
Furthermore, in a retrospective review of the records of the New Zealand National Poisons Centre over
the period 2003-2012, rapidly increasing levels of enquiries were identified for a range of prescription
medicines, including venlafaxine [67]. According to the EMA EV database from the last decade [68],
the misuse-/abuse-/dependence- and withdrawal-related ADRs reported respectively for bupropion
and venlafaxine show that bupropion may possess a higher recreational value due to its dopaminergic
and stimulant-like activity, whilst the occurrence of a venlafaxine-withdrawal syndrome may be
a significant issue for venlafaxine-treated patients; these data were confirmed by analysis of the
UK-based Yellow Card Scheme [68].
3.3. Antipsychotics
Consistent with their increased prescription and availability [69], second-generation antipsychotic
(SGA) (e.g., quetiapine and olanzapine) abuse has recently been reported [1,70–72]. Quetiapine
appears to be the most documented SGA being abused; it is commonly administered in the
400–800 mg/day range for the treatment of schizophrenia; bipolar disorder; and as an add-on in
major depression and anxiety [73–76]. Quetiapine is anecdotally known as ‘Susie Q’; ‘Quell’; and
‘baby heroin’ [75–79], with ‘Q ball’ and ‘Maq ball’, respectively, being combinations with cocaine, and
marijuana. Crushed quetiapine tablets can be self-administered through nasal insufflation [79–81],
although both oral [81–84], and intravenous [85–87] routes of administration have been reported.
Consistent with these anecdotal clinical observations, post-marketing surveillance reports indicate
an increase in quetiapine availability on the black-market [75,79,88–90]. Furthermore, quetiapine, either
on its own or in combination with heroin and/or alcohol [91], is consistently associated with high
rates of ambulance attendances, indicating greater community-level harm relative to other atypical
antipsychotics [92]. Indeed, between 2005 and 2011, quetiapine-related Emergency Department visits
increased in the USA by 90%, from 35,581 to 67,497 attendances [93]. A recent US National Poison
Data retrospective analysis identified all cases of single-substance SGA exposures coded as ‘intentional
abuse’ [94] during a 10-year period (2003–2013), quetiapine being the most represented molecule,
followed by risperidone and olanzapine. Prison inmates and opioid addicts seem to represent the most
at-risk populations [24,75,76,95–97]. Quetiapine psychotropic effects [86,87] are associated with both
increased levels of DA in the nucleus accumbens (NAc) area [89,98–100] and D2 receptor blockage.
As some pharmacodynamic mechanisms are shared by other non-misused SGAs [101–104], other
factors [105,106] or pharmacological effects explaining the molecule misuse potential may include
norquetiapine-related norepinephrine reuptake blockade [75], 5-HT7 antagonist properties and sigma
receptor activation [107,108]. Quetiapine pharmacokinetics, mediated by the cytochrome CYP3A4, may
play a part, as well, in facilitating its misuse [109]. Its XR formulation may be less frequently abused,
due to the delayed (by approximately 3 h) and blunted (by approximately 67%) serum peak [88];
the tablet coating may also make snorting of the crushed tablets quite problematic [89].
Another SGA, olanzapine, is normally prescribed at a dosage of 5–20 mg oral daily in order to
treat schizophrenia, bipolar disorder and resistant depression. Whilst being widely prescribed, it has
been anecdotally reported, at dosages up to 50 mg, as the ‘ideal trip terminator/modulator’ after
a psychedelic drug binge [110]. According to discussion forums/specialised websites [111], olanzapine
is also being used to treat unwanted ‘comedown’ symptoms from drug/alcohol intake [112,113].
Consistent with this, clients on methadone maintenance treatment attending the National Drug
Treatment Centre (NDTC) in Dublin reported levels of non-medical use of olanzapine, with dosages
of up to 100 mg/day, in order to manage anxiety and improve sleep, and in a minority of
cases, to ‘get stoned’ [114]. Olanzapine activity involves GABA-A receptors [115], hence the
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associated sedation, the rewarding glutamatergic stimulation of the ventral tegmental area DAergic
neurons [116], the 5HT2C and histamine/H1 antagonist properties and the potent inhibiting action
on the muscarinic M1 receptors [115,116]. In comparing quetiapine with olanzapine through the UK
Prescription Cost Analysis and the Drug Analysis Profiles of the Yellow Card Scheme, quetiapine
was shown to be slightly less frequently prescribed but associated with a smaller total number of
general reports, and hence, a comparatively higher number of abuse/dependence/withdrawal ADR
reports [117,118]. In line with this, the OPPIDUM French addictovigilance network highlighted the
emerging misuse of prescription molecules, and this included quetiapine as well [119]. Information
from the previous 10 years from the EMA EV database relating to quetiapine and olanzapine
misuse/abuse/dependence/withdrawal-related ADR reports [8] shows a higher misuse risk for
quetiapine in comparison with olanzapine for the selected ADR reports. Indeed, quetiapine
XR formulation was represented in only a smalll proportion of misuse cases, with both nasal
and parenteral administration having been identified. Of particular interest was, in comparison
with olanzapine, a higher risk of discontinuation/withdrawal syndrome following the abrupt
cessation of quetiapine [75,113,120]. Finally, consistent with previous data [75,82–85,90,121–123],
the quetiapine- and olanzapine-related fatalities reported on the EMA EV database were typically the
result of a polydrug intake, which included opiates/opioids, antidepressants, and over-the-counter
drugs [124,125].
3.4. Image-And Performance-Enhancing Drugs (IPEDs)
Over the last few decades, a range of prescribed and non-prescribed enhancement drugs have
increasingly been self-administered [72] in order to improve the ageing process, and sexual performances,
and to reduce hair loss, fatigue and other physiological conditions which are, at times, considered
pathological in a society that strongly emphasises the importance of physical appearance [126].
Prescribed image- and performance-enhancing drugs (IPEDs) include anabolic-androgenic steroids
(AAS), human growth hormone (hGH), steroid hormones (e.g., androstenedione), insulin, erythropoietin,
diuretics, but also, β-2 agonists (e.g., clenbuterol and salbutamol) [127]. Their misuse is typically
carried out within a polypharmacy context [128] with alcohol, cannabis/cannabinoids, cocaine,
amphetamines/methamphetamines being ingested as ancillary drugs. Moreover, the recent reporting of
IPED injecting practices are a reason for concern [129]; these mostly involve anabolic androgenic steroids,
non-steroidal anabolic hormones (e.g., hGH and insulin), tanning peptides, cosmetic injectables such as
botox and dermal fillers, etc. [130–132]. Among non-steroidal anabolic hormones, insulin seems to be
misused for performance-enhancement purposes through several administration routes (intravenous,
intramuscular and subcutaneous); indeed, insulin may help in achieving a decrease in fat deposition, an
increase in muscle mass and positive mood changes, although serious hypoglycaemic episodes and other
medical sequelae can occur as well [133,134]. Within the IPED group, anti-asthmatic beta-2 agonists
have recently emerged as having potential for misuse, e.g., salbutamol for its performance-enhancing
effects and clenbuterol for its hypertrophic and lipolytic effects. They are both included in the list
of prohibited substances released by the World Anti-Doping Agency (WADA) [135], with salbutamol
being allowed only as a component in the treatment regimen for athletes with asthma. Clenbuterol,
even if different from anabolic steroids, has been also prohibited as an anabolic agent since 2006.
In parallel with this, the Food and Drug Administration (FDA) banned the use of clenbuterol in
food animals in 1991 and the European Union (EU) followed suit in 1996 [136]. Beta-2 agonists are
synthetic molecules with sympathomimetic activity, prescribed as bronchodilators for the treatment
of asthma. Clenbuterol is licensed for human use only in a few countries (Austria, Germany, Italy,
Spain and Mexico), but not in the UK or the USA [137]. Clenbuterol, as a ‘size zero pill’, is popular
and widely available on the web, being considered an ergo/thermogenic drug and hence, an anabolic
burner [138], similar to caffeine, ephedrine, and thyroid hormones. Clenbuterol-associated lypolisis
can occur via both β-2 adrenergic agonism and its specific action on the adipocytes’ β-3 adrenergic
receptors, which further facilitates lipolysis and weight loss [139–141]. While anti-asthmatic clenbuterol
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dosage ranges between 20 and 40mcg daily, the typical ‘fat burning’ dose is in the 120–160 mcg daily
range; dosage starts at 40 mcg daily, gradually increases, and then remains at the highest dosage for
a duration of 2–4 weeks [142]. In parallel with this, recent years have seen an increase in clenbuterol
exposure reported to poison control centres [143], with the molecule being used either as a dietary
supplement [144] or as an adulterant in illicit drugs, such as cocaine [145]. Its adverse effects are
dose-dependent and may include dysrhythmias and myocardial injury, headache, abdominal pain,
nausea, and rhabdomyolysis [136,146–148]. Reports relating to salbutamol misuse have been less
frequently mentioned [149–151]. Similar to clenbuterol, salbutamol’s adverse effects are dose-related
and may include tremor, restlessness, anxiety/agitation, tachycardia, atrial fibrillation, and myocardial
ischaemia, especially in cases of overdosage, chronic use, or intravenous injection [152]. With respect to
salbutamol, clenbuterol’s higher levels of abuse potential could be associated with its pharmacological
characteristics [143], such as its prolonged elimination half-life (35 h) and its higher lipophilicity, which
can be associated with a fast transition through the blood–brain barrier. Consistent with this, salbutamol
has been described as significantly less potent on a reinforcement schedule than clenbuterol [149,152–154].
Clenbuterol abuse-related fatalities have consistently been reported in the literature [136,140,147,155],
whilst salbutamol is considered safer [156]. In this regard, Milano et al. [10] studied the 2006–2016
EMA clenbuterol- and salbutamol-related, misuse/abuse/dependence/withdrawal/overdose/off-label
spontaneous reports. They found that clenbuterol, in comparison with salbutamol, had higher levels of
misuse/abuse. These clenbuterol-related data were most typically from males and were associated with
the intake of steroids [10], hence confirming previous reports [157,158].
3.5. Over-The-Counter (OTC) Medicines—Loperamide
Currently, over-the-counter (OTC) abuse (‘pharming’) is an internationally recognised problem,
and the recent emergence of new forms, including online, of medicine supply, is alarming clinicians
and health authorities nationwide. The EU introduced a strong legal framework for the licensing,
manufacturing and distribution of medicines [159], but no measures have been taken so far for the
distribution of OTC drugs, and it is hence, difficult to quantify their actual misuse and abuse [159–168].
Over previous years, the OTC antidiarrhoeal medicine loperamide has increasingly been reported
as being diverted and used to achieve recreational effects [159–162]. Loperamide acts as a potent
mu-opioid receptor agonist, albeit with predominantly peripheral activity on the myenteric plexus,
hence primarily increasing the intestinal transit time by decreasing propulsive activity. Secondary
peripheral effects are seen at κ-opioid and δ-opioid receptors as well [169,170]. Loperamide was
initially placed by the US FDA in Schedule V of the Controlled Substance Act but then, after having
assessed its safety profile with the conclusion of low levels of physical dependence risk, in 1988,
it was made available for OTC use. In the 2–16 mg daily dosage, loperamide is considered safe
and devoid of misuse abuse potential because of its rapid metabolism and poor blood–brain barrier
(BBB) penetration. In doses of 50–300 mg, however, loperamide ingestion has been associated with
euphoria, central nervous system depression [171–174] and even death [175]. Its diversion potential
may be associated with its use as a relief from opioid withdrawal [176]. Anecdotally described as
the ‘poor’s’ methadone’ [177], detailed loperamide dosage titration regimens are being reported
online [20]. Related misuse case series [178] have reported both extremely high daily intakes (up to
1200 mg), and associated cardiotoxicity issues, such as QTc prolongation and torsades de pointes,
QRS prolongation, ventricular dysrhythmias [179–182], syncope, and cardiac arrest [12,179,183,184].
The cardiotoxicity mechanism of loperamide is not clearly understood, although it may be due to
potent inhibition of cardiac ion channels which is, in turn, associated with delayed repolarisation
and QT prolongation [185–187]. Consequently, the FDA [175] has recently warned clinicians and
users about the combination of loperamide with other drugs or herbal products that are known to
prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III drugs (e.g.,
amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine,
ziprasidone), antibiotics (e.g., moxifloxacin), and methadone. Loperamide ingestion has also been
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reported in association with P-glycoprotein (P-gp) substrates (e.g., quetiapine, cetirizine, oxycodone)
or inhibitors (e.g., fluoxetine, citalopram, sertraline, omeprazole, quinine, quinidine, propranolol,
ritonavir). These associations are associated with an increase in the low bioavailability of loperamide,
normally being <2%; plasmatic concentration; levels of euphoric effects; the capacity of possible
contrasting opioid withdrawal symptoms [186–189]; and toxicity effects [175]. Concurrent use of
loperamide with CYP3A4 inhibitors (e.g., itraconazole, grapefruit juice, omeprazole, tonic water
and cimetidine) or CYP2C8 inhibitors (e.g., gemfibrozil) can increase its plasma levels as well, with
recurrent ventricular tachycardia having been reported in a patient who was taking large recreational
doses of both loperamide and the CYP3A4 inhibitor, famotidine [190]. Treatment of loperamide
intoxication involves the use of naloxone, which may not be able to directly reverse loperamide
cardiotoxic effects [191,192].
4. Discussion
The ever-increasing number of NPS emerging worldwide and the parallel changes in drug
scenarios represent a challenge for psychiatric, public health and drug-control policies [193]. In line
with this, the current systematic review has focused on a different range of prescribed medications
which are indeed being used as NPS [1]. Within both online drug forum communities and social
networks, there are some educated/informed users (the ‘psychonauts’) [194] who typically ‘test’
a range of psychotropics, including prescribed drugs, to achieve specific mindsets and eventually,
share this information with peers [193]. However, in parallel with recently increased levels of access to
the web, a large number of vulnerable subjects, including both children/adolescents and psychiatric
patients, have been exposed to a range of ‘pro-drug’ information, and this is a reason for concern [193].
Although a number of online ‘rogue’ pharmacies have been shut down, this typically prompts the
sellers to move to servers in overseas countries, leading to a growing black market [195].
It is intriguing that, for the range of prescription molecules discussed, including the fairly recently
introduced gabapentinoids, pre-marketing processes were not been able to appropriately identify their
abuse/misuse potential. However, similar to what happened with benzodiazepines and z-hypnotics,
this potential has finally emerged over time. Present data seem to suggest that abuse liability-focused,
pre-marketing laboratory testing may need to consider interaction studies with alcohol and/or other
drugs [194,196]. Furthermore, post-marketing surveillance for substance abuse [197] should routinely
be carried out to assess the abuse potential of newly released drugs, especially those with activity on
the central nervous system (CNS) [198]. Indeed, lack of information on the abuse/misuse potential
of a new medicine’s interaction with the CNS does not mean that a specific medicine does not
actually produce these effects. Furthermore, in order to look at how medicines are actually used in
real life, modern pharmacovigilance should identify a range of technical tools and approaches to
go beyond spontaneous reporting systems. Physicians should be vigilant when prescribing drugs
with an abuse/misuse/diversion potential and carefully evaluate the possibility for some clients
(inmates; people with a personal history of misuse or abuse) to be more vulnerable to these misuse
activities. Finally, while a continuum of related professional training is needed, it may be important to
consider a strategy to increase clients’ access to treatment services, possibly through enhanced links
between community pharmacists, who are the first professionals to identify a repeat supply issue, and
prescribers/clinicians [198].
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